Galux, a South Korean biotech company, raised $29 million (KRW 42 billion) in Series B funding on February 9-10, 2026, bringing total funding to $47 million.123
The round included returning investors InterVest, DAYLI Partners, PATHWAY Investment, and new investors like Yuanta Investment, Korea Development Bank, SL Investment, NCORE Ventures, Sneak Peek Investments, Korea Investment & Securities, Mirae Asset Securities.123
Funds will enhance AI platform for de novo protein design, expand R&D, and advance preclinical pipelines targeting difficult areas like GPCRs and ion channels.123
Galux has partnerships with Celltrion, LG Chem, and recently Boehringer Ingelheim.123
Previous $18M Series A was in 2022.123
No specific details found in search results on CSL teaming up with Memo.
Sources:
1. https://technews180.com/funding-news/galux-raises-29m-series-b-for-ai-protein-design/
2. https://www.bastillepost.com/global/article/5599080-galux-raises-29m-series-b-to-advance-ai-driven-protein-design-for-drug-discovery
3. https://www.biospace.com/press-releases/galux-raises-29m-series-b-to-advance-ai-driven-protein-design-for-drug-discovery